Publications by authors named "Mayuko Tashima"
The efficacy and safety of the combination of biologic therapies remain unclear with an ineffective and insufficient single biologic for managing asthma. Herein, we report two cases using dual biologics for severe asthma and atopic dermatitis. A 52-year-old male patient who received dupilumab and mepolizumab, benralizumab, or tezepelumab, followed by bronchial thermoplasty, and a 41-year-old male patient who received dupilumab and omalizumab, both experienced improved asthma and atopic dermatitis.
View Article and Find Full Text PDFObjective: Systemic corticosteroid administration, also called short bursts (SB), is harmful for patients with asthma; however, the actual burden of one-day SB remains unsolved. This study aimed to elucidate the characteristics of patients requiring one-day SB against asthma in clinical practice.
Methods: Consecutive patients who regularly visited our hospital for asthma treatment between January 2019 and December 2020 were reviewed and followed for one year.
Article Synopsis
- Disinhibition during bronchoscopy with sedation is a concern, with a study finding that 19.5% of patients experienced moderate to severe disinhibition while using midazolam.
- The study reviewed 251 patients and classified disinhibition into mild, moderate, and severe categories, highlighting that factors like depression and the use of endobronchial ultrasound increased its likelihood.
- Interestingly, patients with moderate disinhibition reported less discomfort during the procedure, and overall hemodynamic changes were similar across disinhibition severity levels.
Objective: The data on intermittent systemic corticosteroid therapy for asthma exacerbation, clinically called a "short burst," is limited. This study aimed to investigate the characteristics of patients with frequent systemic corticosteroid bursts for asthma in real clinical practice.
Methods: Consecutive patients who regularly visited our hospital for asthma treatment between January 2019 and December 2020 were reviewed.